Total
0
Shares
Sourced: Shutterstock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Neurotech International’s (NTI) medical-neurofeedback headband, Mente, has received CE Mark renewal
  • This renewal confirms Mente’s position as a leading device for at-home use when managing autism symptoms
  • Mente is the world’s only clinically proven at-home therapy for children with an autism spectrum disorder
  • It is a soft and portable headband which is designed to rebalance brain waves such as Delta and Beta which can be found in neurodevelopmental disorders
  • Mente helps ASD children feel more relaxed, focused and engaged with their surroundings
  • Shares in Neurotech remain flat on the market and are trading for 1.2 cents each

Neurotech International’s (NTI) flagship device, Mente, has received CE Mark renewal.

This renewal confirms Mente’s position as a medical-neurofeedback device designed to be used at home for managing autism.

The CE renewal review was conducted by ITALCERT, which evaluated Neurotech’s management system and the compliance of the Mente device to the European
standards of health, safety and effectiveness.

“With CE certification, Neurotech meets all the required standards and policies required of an organisation in this market,” CEO Peter Griffiths said.

“Over the past year, we have listened to feedback from our customers and distribution partners and many of the improvements we have introduced reflect this feedback,” Peter added.

Mente is currently the world’s only clinically proven at-home therapy for children with autism spectrum disorder (ASD).

Essentially, Mente is a soft, easy to use and portable headband that was developed as a home-based treatment to help children with ASD better self-regulate and feel more relaxed and engaged.

How does it work?

Mente is designed to rebalance low and high-frequency brainwaves, such a Delta and Beta, which can be found in neurodevelopmental disorders and learning difficulties. These unbalanced brain patterns can cause a lack of focus, impulsive and obsessive behaviour, anxiety, as well as sleep and memory problems.

The device gives audio feedback through earphones to help the brain feel more relaxed. As the brain activity starts to rebalance, Mente helps the child better engage with their surroundings.

Shares in Neurotech remain flat on the market and are trading for 1.2 cents each at 11:06 am AEST.

NTI by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.